Johnson & Johnson highlights cancer and neuroscience focus, steering away from obesity drug push
In a June 17 comment covered by Yahoo Finance, Johnson & Johnson’s chief executive said the company does not plan to move into the obesity drug market, while reinforcing a strategy centered on oncology and neuroscience.